Patient characteristics and response to high-dose cyclophosphamide
| Patient no. . | Age; sex . | Antibody type (disease duration) . | Associated disease . | Prior therapy . | Pretreatment status . | Status at discharge . | Current status . | Months of follow-up . |
|---|---|---|---|---|---|---|---|---|
| 1 | 56; F | Warm DAT (+); cold agg. (+) (9 y) | None | Glucocorticoids, splenectomy, oral cyclophosphamide, cyclosporine | HB 5 g/dL*; DAT (+); cold agg (+); no therapy | HB 9.9 g/dL; DAT (+); cold agg (+) | PR HB 11.1 g/dL; DAT (+); cold agg (+); off therapy | 29 |
| 2 | 52; M | Warm DAT (+) (4 mo) | None | Glucocorticoids, splenectomy, azathioprine, hydroxychloroquine, ascorbic acid, intravenous immunoglobulin | HB 6 g/dL; DAT (+); prednisone 30 mg | HB 9.0 g/dL; DAT (+); prednisone 30 mg | CR HB 13.7 g/dL; DAT (−); off therapy | 16 |
| 3 | 55; F | Warm DAT (+) (18 mo) | None | Glucocorticoids, cyclosporine, intravenous immunoglobulin | HB 6.8 g/dL; DAT (+); prednisone 40 mg | HB 9.0 g/dL; DAT (+); prednisone 40 mg | CR HB 14.7 g/dL; DAT (−); off therapy | 15 |
| 4 | 64; M | Cold agg (+) (40 mo) | None | Glucocorticoids, chlorambucil | HB 10 g/dL; cold agg (+); prednisone 40 mg | HB 9.0 g/dL; cold agg (+); prednisone 40 mg | CR HB 15 g/dL; cold agg (+); off therapy | 16 |
| 5 | 39; M | Warm DAT (+) (12 mo) | None | Glucocorticoids, intravenous immunoglobulin, oral cyclophosphamide | HB 5 g/dL; DAT (+); prednisone 60 mg | HB 9.6 g/dL; DAT (+); prednisone 40 mg | CR HB 14 g/dL; DAT (+); off therapy | 18 |
| 6 | 7; M | Warm DAT (+) (46 mo) | GVHD following allogeneic BMT at age 2 y for Hurler syndrome | Glucocorticoids, azathioprine, mycophenolate mofetil, FK 506, intravenous immunoglobulin | HB 6.5 g/dL; DAT (+); prednisolone 35 mg, FK 506 (3 mg) | HB 7.1 g/dL; DAT (+); prednisolone 35 mg, FK 506 (0.4 mg) | PR HB 13.8 g/dL; DAT (+); dexamethasone 1.75 mg; QOD† rituximab | 15 |
| 7 | 45; F | Warm DAT (+) (23 mo) | Castleman disease | Glucocorticoids, rituximab | HB 6.5 g/dL; DAT (+); no therapy | HB 10.4 g/dL; DAT (+); no steroids | PR HB 14 g/dL; DAT (+); rituximab | 15 |
| 8 | 55; M | Warm DAT (+) (3 mo) | Chronic lymphocytic leukemia | Glucocorticoids | HB 6.9 g/dL; DAT (+); prednisone 50 mg | HB 14.3 g/dL; DAT (+); prednisone 20 mg | CR HB 14.9 g/dL; DAT (+); off therapy | 11 |
| 9 | 48; F | Warm DAT (+) (on and off 30 y) | None | Glucocorticoids, splenectomy, vincristine, intravenous immunoglobulin, danazol, plasmapheresis, ascorbic acid | HB 6.7 g/dL; DAT (+); prednisone 60 mg | HB 8.4 g/dL; DAT (+); prednisone 40 mg | CR HB 13.7 g/dL; DAT (+); prednisone 5 mg QOD† | 4 |
| Patient no. . | Age; sex . | Antibody type (disease duration) . | Associated disease . | Prior therapy . | Pretreatment status . | Status at discharge . | Current status . | Months of follow-up . |
|---|---|---|---|---|---|---|---|---|
| 1 | 56; F | Warm DAT (+); cold agg. (+) (9 y) | None | Glucocorticoids, splenectomy, oral cyclophosphamide, cyclosporine | HB 5 g/dL*; DAT (+); cold agg (+); no therapy | HB 9.9 g/dL; DAT (+); cold agg (+) | PR HB 11.1 g/dL; DAT (+); cold agg (+); off therapy | 29 |
| 2 | 52; M | Warm DAT (+) (4 mo) | None | Glucocorticoids, splenectomy, azathioprine, hydroxychloroquine, ascorbic acid, intravenous immunoglobulin | HB 6 g/dL; DAT (+); prednisone 30 mg | HB 9.0 g/dL; DAT (+); prednisone 30 mg | CR HB 13.7 g/dL; DAT (−); off therapy | 16 |
| 3 | 55; F | Warm DAT (+) (18 mo) | None | Glucocorticoids, cyclosporine, intravenous immunoglobulin | HB 6.8 g/dL; DAT (+); prednisone 40 mg | HB 9.0 g/dL; DAT (+); prednisone 40 mg | CR HB 14.7 g/dL; DAT (−); off therapy | 15 |
| 4 | 64; M | Cold agg (+) (40 mo) | None | Glucocorticoids, chlorambucil | HB 10 g/dL; cold agg (+); prednisone 40 mg | HB 9.0 g/dL; cold agg (+); prednisone 40 mg | CR HB 15 g/dL; cold agg (+); off therapy | 16 |
| 5 | 39; M | Warm DAT (+) (12 mo) | None | Glucocorticoids, intravenous immunoglobulin, oral cyclophosphamide | HB 5 g/dL; DAT (+); prednisone 60 mg | HB 9.6 g/dL; DAT (+); prednisone 40 mg | CR HB 14 g/dL; DAT (+); off therapy | 18 |
| 6 | 7; M | Warm DAT (+) (46 mo) | GVHD following allogeneic BMT at age 2 y for Hurler syndrome | Glucocorticoids, azathioprine, mycophenolate mofetil, FK 506, intravenous immunoglobulin | HB 6.5 g/dL; DAT (+); prednisolone 35 mg, FK 506 (3 mg) | HB 7.1 g/dL; DAT (+); prednisolone 35 mg, FK 506 (0.4 mg) | PR HB 13.8 g/dL; DAT (+); dexamethasone 1.75 mg; QOD† rituximab | 15 |
| 7 | 45; F | Warm DAT (+) (23 mo) | Castleman disease | Glucocorticoids, rituximab | HB 6.5 g/dL; DAT (+); no therapy | HB 10.4 g/dL; DAT (+); no steroids | PR HB 14 g/dL; DAT (+); rituximab | 15 |
| 8 | 55; M | Warm DAT (+) (3 mo) | Chronic lymphocytic leukemia | Glucocorticoids | HB 6.9 g/dL; DAT (+); prednisone 50 mg | HB 14.3 g/dL; DAT (+); prednisone 20 mg | CR HB 14.9 g/dL; DAT (+); off therapy | 11 |
| 9 | 48; F | Warm DAT (+) (on and off 30 y) | None | Glucocorticoids, splenectomy, vincristine, intravenous immunoglobulin, danazol, plasmapheresis, ascorbic acid | HB 6.7 g/dL; DAT (+); prednisone 60 mg | HB 8.4 g/dL; DAT (+); prednisone 40 mg | CR HB 13.7 g/dL; DAT (+); prednisone 5 mg QOD† | 4 |
DAT indicates direct antiglobulin (Coombs) test; cold agg, cold-agglutinin screen; HB, hemoglobin in g/dL; PR, partial response; CR, complete response; GVHD, graft-versus-host disease; and BMT, bone marrow transplantation.
g/dL represents the hemoglobin with packed red blood cell transfusion; all other hemoglobin values represent nontransfused values.
QOD indicates every other day; prednisone doses reflect daily dosage unless stated otherwise.